quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:08:02·1205d
INSIDERFiling
Oyster Point Pharma Inc. logo

SEC Form 4: Santel Donald J returned 8,198 shares to the company, closing all direct ownership in the company to cover withholding tax

OYST· Oyster Point Pharma Inc.
Health Care
Original source

Companies

  • OYST
    Oyster Point Pharma Inc.
    Health Care

Recent analyst ratings

  • Aug 11UpdateChardan Capital Markets$22.00
  • Jul 18UpdateH.C. Wainwright$20.00
  • Nov 9UpdateJP Morgan$23.00

Related

  • NEWS792d
    Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
  • 13D/G1164d
    SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
  • 13D/G1164d
    SEC Form SC 13G/A filed by Oyster Point Pharma Inc. (Amendment)
  • SEC1196d
    SEC Form 15-12G filed by Oyster Point Pharma Inc.
  • SEC1196d
    Oyster Point Pharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits (Amendment)
  • 13D/G1196d
    SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
  • 13D/G1200d
    SEC Form SC 13D/A filed by Oyster Point Pharma Inc. (Amendment)
  • SEC1204d
    SEC Form EFFECT filed by Oyster Point Pharma Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022